Clinkenbeard Erica
Department of Medical and Molecular Genetics, School of Medicine, Indiana University, 635 Barnhill Drive MS 5023, Indianapolis, IN, 46202, USA.
Calcif Tissue Int. 2023 Jul;113(1):4-20. doi: 10.1007/s00223-023-01092-1. Epub 2023 Jun 12.
Mineral homeostasis of calcium and phosphate levels is one critical component to the maintenance of bone mineral density (BMD) and strength. Diseases that disrupt calcium and phosphate balanced have highlighted not only the role these minerals play in overall bone homeostasis, but also the factors, hormones and downstream transporters, responsible for mineral metabolism. The key phosphaturic hormone elucidated from studying rare heritable disorders of hypophosphatemia is Fibroblast Growth Factor 23 (FGF23). FGF23 is predominantly secreted from bone cells in an effort to maintain phosphate balance by directly controlling renal reabsorption and indirectly affecting intestinal uptake of this mineral. Multiple factors have been shown to enhance bone mRNA expression; however, FGF23 can also undergo proteolytic cleavage to control secretion of the biologically active form of the hormone. The review focuses specifically on the regulation of FGF23 and its secretion from bone as well as its hormonal actions under physiological and disease conditions.
钙和磷水平的矿物质稳态是维持骨矿物质密度(BMD)和骨强度的一个关键组成部分。扰乱钙磷平衡的疾病不仅凸显了这些矿物质在整体骨稳态中的作用,还揭示了负责矿物质代谢的因素、激素及下游转运体。通过研究罕见的低磷血症遗传性疾病而阐明的关键排磷激素是成纤维细胞生长因子23(FGF23)。FGF23主要由骨细胞分泌,通过直接控制肾脏重吸收和间接影响肠道对这种矿物质的摄取来维持磷平衡。已证实多种因素可增强骨mRNA表达;然而,FGF23也可经历蛋白水解切割以控制该激素生物活性形式的分泌。本综述特别关注FGF23的调节及其从骨中的分泌,以及其在生理和疾病状态下的激素作用。